Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Oncology Research and Treatment

Vol. 39, No. 9, 2016

Issue release date: September 2016

Add all to MyReading List
FREE ONLINE ACCESS
 
493

Editorial Board / Contents / Imprint

Oncol Res Treat 2016;39:493-498 (DOI:10.1159/000449109)
Free Access
Editorial
500

A Change of Paradigm in the Treatment of Cervical Cancer

Mallmann P.
Oncol Res Treat 2016;39:500 (DOI:10.1159/000448967)
Free Access
Review Article
501

Epidemiology and Early Detection of Cervical Cancer

Hillemanns P. · Soergel P. · Hertel H. · Jentschke M.
Oncol Res Treat 2016;39:501-506 (DOI:10.1159/000448385)
Free Access
508

Surgical Treatment of Early-Stage Cervical Cancer

Brucker S.Y. · Ulrich U.A.
Oncol Res Treat 2016;39:508-514 (DOI:10.1159/000448794)
Free Access
516

Radiotherapy of Cervical Cancer

Vordermark D.
Oncol Res Treat 2016;39:516-520 (DOI:10.1159/000448902)
Free Access
522

Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer

Mallmann P. · Mallmann C.
Oncol Res Treat 2016;39:522-524 (DOI:10.1159/000449023)
Editor's Choice - Free Access
525

State-of-the-Art Treatment and Novel Agents in Local and Distant Recurrences of Cervical Cancer

Tempfer C.B. · Beckmann M.W.
Oncol Res Treat 2016;39:525-533 (DOI:10.1159/000448529)
Free Access
Original Article
534

Association of the MTHFR Gene C677T Polymorphism with Breast Cancer in a Turkish Population

Kaya E.F. · Karakus N. · Ulusoy A.N. · Özaslan C. · Kara N.
Oncol Res Treat 2016;39:534-538 (DOI:10.1159/000448084)
Free Access
539

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Reck M. · Thomas M. · Kropf-Sanchen C. · Mezger J. · Socinski M.A. · Depenbrock H. · Soldatenkova V. · Brown J. · Krause T. · Thatcher N.
Oncol Res Treat 2016;39:539-547 (DOI:10.1159/000448085)
Open Access Gateway
Novel Insights from Clinical Practice
548

Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease

Mischler K. · Kneifel S. · Cathomas R.
Oncol Res Treat 2016;39:548-552 (DOI:10.1159/000448387)
Free Access
Ongoing Clinical Trials
553

Ongoing Clinical Trials in Testicular Cancer: The TIGER Trial

Oncol Res Treat 2016;39:553-556 (DOI:10.1159/000448868)
Free Access
Congress Report
557

Therapierelevante Daten zu gastrointestinalen Tumoren beim ASCO 2016

Oncol Res Treat 2016;39:557-559 (DOI:10.1159/000448643)
Free Access
 
560

Reports of Oncological Societies

Oncol Res Treat 2016;39:560-567 (DOI:10.1159/000448982)
Free Access
568

PharmaForum

Oncol Res Treat 2016;39:568-569 (DOI:10.1159/000449112)
Free Access
570

PharmaNews

Oncol Res Treat 2016;39:570-571 (DOI:10.1159/000449113)
Free Access
573

PharmaNews

Oncol Res Treat 2016;39:573-577 (DOI:10.1159/000449114)
Free Access
579

Meetings and Conferences

Oncol Res Treat 2016;39:579-580 (DOI:10.1159/000449068)
Free Access